Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction

Filicori, Marco; Flamigni, Carlo; Cognigni, Graçiela Estela; Dellai, P.; Michelacci, Laura; Arnone, R.

doi:10.1016/s0015-0282(16)56879-4

Cited by 31 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation has been reported previously by Filicori et al (22), who found no differences in the molar glucose-to-insulin ratio between PCOS and PCO, suggesting that insulin resistance is not a feature of patients that they described as having multifollicular ovaries. Our patients included in group II, however, showed significant differences compared to controls, although women in group I had a more profound reduction in their molar glucose-to-insulin ratio than patients included in the remaining groups.…”

Section: Discussionsupporting

confidence: 88%

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Cano

García-Velasco

Millet

et al. 1997

J Assist Reprod Genet

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Cano

García-Velasco

Millet

et al. 1997

J Assist Reprod Genet

View full text Add to dashboard Cite

“…Both of these clinical scenarios are associated with subtle changes in pulsatile FSH secretion so that MFO has generally been considered to be the sonographic equivalent of hypothalamopituitary dysfunction9. Moreover, anovulatory women with MFO may have a mild degree of insulin resistance, which is greater than that of normal ovulatory women but less than that of PCOS patients27. The present study is the first to show that almost 40% of non‐hirsute ovulatory women have at least one MFO detected by TVS.…”

Section: Discussionmentioning

confidence: 62%

Serum high‐molecular weight adiponectin is related to early postprandial glycemic increases and gastric emptying in patients with type 2 diabetes mellitus

Iwase

Iino

Oku

et al. 2009

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Pulsatile GnRH treatment could be considered a safe therapeutic alternative to exogenous gonadotrophins in terms of multiple pregnancies and hyperstimulation risks, even if the effectiveness of such regimen is reduced in PCOS patients, especially when obesity is present [62]. Hyperinsulinism, indeed, is considered a negative prognostic factor as insulin plasma concentrations were demonstrated to be inversely related to the ovulation rate after pulsatile GnRH administration in PCOS women [63].…”

Section: Naltrexone Treatment: Implications For the Management Of Pcomentioning

confidence: 99%

Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities

Guido¹,

Romualdi²,

Lanzone

2006

CPD

View full text Add to dashboard Cite

Beta-endorphin were detected in the endocrine pancreas and seem able to influence insulin and glucagon release. Hence, endogenous opioids could have a role in glucoregulation and in the pathogenesis of obesity beyond the previously detected effects on appetite. Metabolic abnormalities, such as hyperinsulinemia, insulin-resistance and obesity, are common features of polycystic ovary syndrome (PCOS), and seem to have a pathogenetic role in this disorder. A link between opioids and PCOS-related hyperinsulinism is suggested by the finding of altered central opioid tone and elevated beta-endorphins levels, directly correlated with body weight, in these patients. Furthermore, naloxone and naltrexone significantly reduce the insulin response to glucose load only in hyperinsulinemic PCOS patients. This effect is obtained chiefly through an improvement of insulin clearance. Naltrexone is also able to ameliorate the abnormal gonadotrophins secretion and to improve the ovarian responsiveness in obese PCOS women undergoing ovulation induction with exogenous GnRH. Such effects are believed to be obtained through an amelioration of hyperinsulinemia. Gonadal steroids modulate the opioid system both centrally and in peripheral districts. Nevertheless, the decline of ovarian function does not abolish the opioidergic control of glucoregulation. Post-menopausal period is characterised by a high prevalence of hyperinsulinemia and insulin-resistance. In particular, an association between hyperinsulinemia and increased opioid activity was found in postmenopausal women showing a central body fat distribution. Both naloxone and naltrexone ameliorate the metabolic imbalance also when it appears in the climacteric period, and mainly by increasing insulin clearance. The benefits of naltrexone may represent in the future a useful tool for the treatment of women with hyperinsulinism in the clinical practice.

show abstract

Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction

Cited by 31 publications

References 24 publications

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Serum high‐molecular weight adiponectin is related to early postprandial glycemic increases and gastric emptying in patients with type 2 diabetes mellitus

Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities

Contact Info

Product

Resources

About